Literature DB >> 3115136

[Ro 15-1788 antagonizes reliably the Benzodiazepine effect after Flunitrazepam combination anesthesias].

W Tolksdorf, A Pirwitz, C Bentzinger, J Pfeiffer.   

Abstract

INTRODUCTION: The imidazobenzodiazepine Ro 15-1788 has been shown to block the central effects of benzodiazepines without severe side effects in animals studies and human volunteers. Benzodiazepine premedication and benzodiazepine/opioid combinations are often used in anesthesiology. A prolonged benzodiazepine action in combination with narcotics can cause problems in the postoperative period such as respiratory depression or aspiration of gastric contents due to reduced vigilance. Therefore, a reversal of the central effects of benzodiazepines can be of advantage postoperatively. This study was designed to compare the efficacy of Ro 15-1788 and placebo in reversing the central effects of flunitrazepam used to induce and maintain general anesthesia. STUDY
DESIGN: double blind, parallel groups, randomized, placebo-controlled study. 60 patients of both sexes aged 20-65 years, ASA class I-II, who were to undergo elective surgery under general anesthesia with an estimated duration of 90-150 min. Study procedure: Evening premedication: 1-2 mg flunitrazepam orally. Morning premedication: 7.5 mg midazolam orally. Monitoring: blood pressure, heart rate, and ECG continuously. Induction of anesthesia: 0.2 mg fentanyl, 0.03-0.04 mg/kg flunitrazepam, 0.1 mg/kg pancuronium. Endotracheal intubation, mechanical ventilation. Maintenance of anesthesia: N2O/O2 = 2:1, fentanyl, pancuronium, and flunitrazepam depending on clinical response. At the end of surgery and after decurarization (neostigmine 2.5 mg and atropine 0.5 mg) and oxygenation the patients were extubated. Now Ro 15-1788 or placebo in a 5% glucose solution (in the case of Ro 15-1788: 1 ml = 0.1 mg active drug) were administered.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3115136

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  3 in total

Review 1.  Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Timing and side effects of flumazenil for dental outpatients receiving intravenous sedation with midazolam.

Authors:  T Misaki; N Kyoda; S Oka; K Takada; T Kunimatu; A Tajima
Journal:  Anesth Prog       Date:  1997

3.  Antagonism of benzodiazepine-fentanyl anaesthesia with flumazenil.

Authors:  S Kaukinen; J Kataja; L Kaukinen
Journal:  Can J Anaesth       Date:  1990-01       Impact factor: 5.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.